Distinguished in Peripheral T-Cell Lymphoma

Yasuhito Terui

Saitama, JP 
Distinguished in Peripheral T-Cell Lymphoma
Saitama, JP 
OverviewLocationsClinical Research

Overview

Yasuhito Terui practices in Saitama, Japan. Terui is rated as a Distinguished expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Peripheral T-Cell Lymphoma.

Their clinical research consists of co-authoring 89 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 7 articles in the study of Peripheral T-Cell Lymphoma.

Locations

Saitama, Japan
Other Locations
Tokyo, Japan
Morohongo, 3500495, Japan
Iruma, Japan
Yankebetsu, Japan
Ariake, 1358550, Japan
Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Japanese Participants With Relapsed/Refractory Multiple Myeloma
A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Japanese Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Bortezomib, Dexamethasone, Pomalidomide
Study Phase: Phase 1

89 Total Publications

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
Journal: International journal of clinical oncology
Published: April 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Terui's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile